Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

[1]  B. Vincenzi,et al.  Efficacy and safety of frontline systemic therapy for advanced HCC: A network meta-analysis of landmark phase III trials. , 2023, JHEP reports : innovation in hepatology.

[2]  D. Pinato,et al.  NASH and Hepatocellular Carcinoma: Immunology and Immunotherapy , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  P. Galle,et al.  LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC) , 2022, Annals of Oncology.

[4]  A. Cortellini,et al.  Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials. , 2022, European journal of cancer.

[5]  A. Zhu,et al.  Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. , 2022, The Lancet. Oncology.

[6]  Yulei N. Wang,et al.  Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma , 2022, Nature Medicine.

[7]  M. Kudo,et al.  Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. , 2022, NEJM evidence.

[8]  K. Yonemori,et al.  Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. , 2022, The New England journal of medicine.

[9]  M. Kudo,et al.  Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. , 2021, Journal of hepatology.

[10]  M. Kudo,et al.  Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. , 2021, The Lancet. Oncology.

[11]  Jianji Pan,et al.  Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study) , 2021, Journal for ImmunoTherapy of Cancer.

[12]  Jinhai Wang,et al.  Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. , 2021, The Lancet. Oncology.

[13]  Ying Cheng,et al.  Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. , 2021, The lancet. Gastroenterology & hepatology.

[14]  A. Griffioen,et al.  Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes , 2021, Nature Reviews Clinical Oncology.

[15]  I. Amit,et al.  NASH limits anti-tumour surveillance in immunotherapy-treated HCC , 2021, Nature.

[16]  C. Porta,et al.  Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. , 2021, The New England journal of medicine.

[17]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[18]  Ying Cheng,et al.  Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy , 2020, Clinical Cancer Research.

[19]  T. Powles,et al.  Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. , 2020, The Lancet. Oncology.

[20]  Jianming Xu,et al.  Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial , 2020, Clinical Cancer Research.

[21]  G. Gao,et al.  N‐glycosylation of PD‐1 promotes binding of camrelizumab , 2020, EMBO reports.

[22]  M. Kudo,et al.  Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  R. Pazdur,et al.  FDA analysis of ECOG performance status and safety outcomes. , 2020 .

[24]  Y. Ba,et al.  Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. , 2020, The Lancet. Oncology.

[25]  Yulei N. Wang,et al.  Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.

[26]  W. Fang,et al.  Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial , 2020, Journal of Hematology & Oncology.

[27]  W. Fang,et al.  Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. , 2020, The Lancet. Oncology.

[28]  P. Lampertico,et al.  Epidemiology and surveillance for hepatocellular carcinoma: New trends. , 2020, Journal of hepatology.

[29]  R. Jhaveri,et al.  Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection , 2019, Hepatology.

[30]  M. Kudo,et al.  Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  V. Mallet,et al.  Hepatitis C virus infection in patients with cancer: impact on clinical trial enrollment, selection of therapy, and prognosis. , 2019, Gastroenterology.

[32]  S. Keam,et al.  Camrelizumab: First Global Approval , 2019, Drugs.

[33]  E. Schmidt,et al.  Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. , 2019, The Lancet. Oncology.

[34]  L. Mazzucchelli,et al.  Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study , 2019, British Journal of Cancer.

[35]  T. Powles,et al.  Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[36]  X. Yi,et al.  Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study , 2018, Clinical Cancer Research.

[37]  Likun Chen,et al.  Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. , 2018, The Lancet. Oncology.

[38]  M. Kudo,et al.  Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. , 2018, The Lancet. Oncology.

[39]  L. Scott.  Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers , 2018, Drugs.

[40]  M. Kudo,et al.  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.

[41]  T. Liang,et al.  Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions. , 2017, Gastroenterology.

[42]  Masao Iwata,et al.  Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models , 2014, Journal of thyroid research.

[43]  Yongchang Shi,et al.  Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth , 2011, Molecular Cancer Therapeutics.

[44]  L. Lou,et al.  YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor‐2 tyrosine kinase with potent activity in vitro and in vivo , 2011, Cancer science.

[45]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[46]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.